Catabasis Pharmaceuticals IPO Research Information

Catabasis Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Catabasis Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Catabasis Pharmaceuticals	CATB - NASDAQ	$13.00-$15.00	$12.00	$12.74	5 million	6/25/2015
Underwriter(s): Citigroup, Cowen & Co.
Co-Manager(s): Oppenheimer & Co., WedBush PacGrow
Industry: Health Care
Filing(s): Filed 2015-05-13 Terms Added 2015-06-11

Catabasis Pharmaceuticals Quote & Chart - Click for current quote - CATB

About Catabasis Pharmaceuticals (adapted from Catabasis Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on our proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "CATB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.